%0 Journal Article
%A Köbel, Martin
%A Yang, Rui Zhe
%A Kang, Eun Young
%A Al-Shamma, Zainab
%A Cook, Linda S
%A Kinloch, Mary
%A Carey, Mark S
%A Hopkins, Laura
%A Nelson, Gregg S
%A McManus, Kirk J
%A Vizeacoumar, Frederick S
%A Vizeacoumar, Franco J
%A Freywald, Andrew
%A Fu, YangXin
%A Reuss, David E
%A Lee, Cheng-Han
%T Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
%J Gynecologic oncology
%V 178
%@ 0090-8258
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2023-02050
%P 80 - 88
%D 2023
%X Inhibition of the MAPK pathway by MEK inhibitors (MEKi) is currently a therapeutic standard in several cancer types, including ovarian low-grade serous carcinoma (LGSC). A common MAPK pathway alteration in tubo-ovarian high-grade serous carcinoma (HGSC) is the genomic inactivation of neurofibromin 1 (NF1). The primary objectives of our study were to survey the prevalence of NF1 inactivation in the principal ovarian carcinoma histotype as well as to evaluate its associations with clinico-pathological parameters and key biomarkers including BRCA1/2 status in HGSC.A recently commercialized NF1 antibody (clone NFC) was orthogonally validated on an automated immunohistochemistry (IHC) platform and IHC was performed on tissue microarrays containing 2140 ovarian carcinoma cases. Expression was interpreted as loss/inactivated (complete or subclonal) versus normal/retained.Loss of NF1 expression was detected in 250/1429 (17.4
%K High-grade serous carcinoma (Other)
%K NF1 (Other)
%K Ovarian cancer (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37820398
%R 10.1016/j.ygyno.2023.09.016
%U https://inrepo02.dkfz.de/record/284647